Most Read Articles
22 May 2017
Chronic obstructive pulmonary disease (COPD) is currently the 10th commonest cause of death in Singapore, with a disease burden of 5.9 percent according to a 2015 population-based survey (EPIC-Asia survey) in Singapore. Pearl Toh spoke with Dr Augustine Tee, chief and senior consultant of the Department of Respiratory and Critical Care Medicine at Changi General Hospital (CGH) in Singapore, on how COPD is often underdetected in the primary care population as symptoms are not specific and diagnosis requires a combination of clinical risk factors, symptoms and spirometry testing.
15 Aug 2017
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
04 Aug 2017
Chronic obstructive pulmonary disease (COPD) is the fourth cause of global mortality, with experts predicting a potential future rise in the prevalence rates of COPD. 
11 May 2016

In conjunction with World Asthma Day which falls on 3rd May 2016, MIMS Doctor speaks to a renowned respiratory medicine specialist, Dato' Dr. Hj Abdul Razak Abdul Muttalif, regarding the chronic airway disease.

CPAP improves altered plasma fibrin clot properties in hypertensive patients with OSA

17 Apr 2017

Treatment with continuous positive airway pressure (CPAP) significantly improves unfavourable prothrombotic fibrin clot characteristics, including hypofibrinolysis, which are common in hypertensive patients with obstructive sleep apnoea (OSA), according to a recent study.

A total of 50 hypertensive patients with clinically significant OSA (age 50.0 ±8.8 years; 39 males) were analysed, and 38 hypertensive patients with OSA balanced for age, sex, blood pressure, cardiovascular risk factors and metabolic status served as controls. Researchers determined plasma fibrin clot properties, including clot permeability coefficient, clot lysis time (CLT) and turbidimetric parameters of clot formation.

OSA patients had more compact fibrin structure (lower median clot permeability coefficient, 6.00 vs 7.25 10−9 cm2; p<0.001), impaired fibrinolysis (longer median CLT, 108.00 vs 92.50 min; p<0.001) and faster clot formation (shorter median lag phase, 40.50 vs 42.50 s; p=0.041), and higher median maximum clot absorbency indicating denser fibrin networks (0.87 vs 0.81; p=0.028) than controls.

Clot permeability coefficient and CLT were associated with apnoea‒hypopnoea index (r=‒0.46; p<0.001 and r=0.44; p<0.001, respectively) as well as with mean (r=0.31; p=0.003; r=‒0.36; p=0.001, respectively) and minimal oxygen saturation (r=0.46; p<0.001; r=‒0.49; p<0.001, respectively).

Treatment with CPAP for 3 months resulted in an increase in clot permeability coefficient (5.95 vs 7.60 10−9 cm2; p=0.001), shortened CLT (107.00 vs 87.00; p=0.006), a longer lag phase of fibrin formation (40.00 vs 43.50 s; p=0.013) and a trend toward lower maximum clot absorbency (0.86 vs 0.81; p=0.058).

A 2011 study found that CPAP treatment for OSA improves postprandial triglyceride concentration curve and cholesterol levels, which may reduce the risk of cardiovascular events. [Am J Respir Crit Care Med 2011;184:355-61]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
22 May 2017
Chronic obstructive pulmonary disease (COPD) is currently the 10th commonest cause of death in Singapore, with a disease burden of 5.9 percent according to a 2015 population-based survey (EPIC-Asia survey) in Singapore. Pearl Toh spoke with Dr Augustine Tee, chief and senior consultant of the Department of Respiratory and Critical Care Medicine at Changi General Hospital (CGH) in Singapore, on how COPD is often underdetected in the primary care population as symptoms are not specific and diagnosis requires a combination of clinical risk factors, symptoms and spirometry testing.
15 Aug 2017
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
04 Aug 2017
Chronic obstructive pulmonary disease (COPD) is the fourth cause of global mortality, with experts predicting a potential future rise in the prevalence rates of COPD. 
11 May 2016

In conjunction with World Asthma Day which falls on 3rd May 2016, MIMS Doctor speaks to a renowned respiratory medicine specialist, Dato' Dr. Hj Abdul Razak Abdul Muttalif, regarding the chronic airway disease.